2025-07-26 - Analysis Report
Okay, here's a report summarizing the analysis of Recursion Pharmaceuticals Inc. (RXRX), presented with key numerical data and brief analysis, followed by a comprehensive summary.

## Recursion Pharmaceuticals Inc. (RXRX) - Stock Analysis Report

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

**Key Metrics:**

*   **RXRX Cumulative Return:** -39.95%
*   **VOO Cumulative Return:** 38.76%
*   **Divergence (RXRX - VOO):**
    *   **Current:** -75.7
    *   **Max:** 35.8
    *   **Min:** -88.1
    *   **Relative Divergence:** 10.0

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO). The current divergence is deeply negative, indicating substantial underperformance. The relative divergence of 10.0 suggests that the current underperformance is near the lower end of its historical range relative to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
| :--------- | :----- | :----- | :------ | :----- | :------ |
| 2021-2023  | 5.0%   | 73.6% | -1.0%   | -0.1   | 4.3    |
| 2022-2024  | 0.0%   | 73.6% | -25.0%  | 0.1    | 2.9    |
| 2023-2025  | 12.0%  | 73.6% | -40.0%  | 0.1    | 2.8    |

**Analysis:** The table shows a high Maximum Drawdown (MDD) of 73.6% across all periods, indicating significant risk. Alpha is consistently negative, suggesting underperformance relative to its benchmark, not explained by market movements. Beta is close to zero or slightly positive, suggesting RXRX's price movement is not strongly correlated with the market. The company's market capitalization has slightly decreased from 4.3 billion to 2.8 billion over the observed periods.

### 2. Recent Price Action

**Key Metrics:**

*   **Current Price:** \$6.49
*   **Previous Close:** \$6.26
*   **Change:** 3.67%
*   **5-day Moving Average:** \$6.424
*   **20-day Moving Average:** \$5.598
*   **60-day Moving Average:** \$5.0377

**Analysis:**  The current price is above the 5-day, 20-day, and 60-day moving averages, indicating a short-term upward trend. The price has recently increased by 3.67% which indicates a short-term, positive movement.

### 3. Market Risk Indicators and Expected Return

**Key Metrics:**

*   **Market Risk Indicator (MRI):** 0.3301 (Low Risk)
*   **RSI:** 75.08 (Overbought)
*   **PPO:** 1.6856
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Delta Previous Relative Divergence (20-day):** 8.1 (+) - Short-term increase
*   **Expected Return:** -228.1%

**Analysis:** The MRI suggests low market risk. The RSI of 75.08 indicates the stock may be overbought. The positive change in relative divergence over the past 20 days indicates a short-term upward trend. The Hybrid Signal suggests buying 80% with caution. The Expected Return is significantly negative, indicating potential long-term underperformance compared to the S&P 500. The substantial 3.67% increase from the previous close may indicate a short-term buying opportunity, though caution is warranted given the negative expected return and overbought RSI.

### 4. Recent News & Significant Events

*   **2025-07-26:** RXRX has recently made headlines due to major business developments, regulatory changes, or market events.
*   **2025-07-24:** Analysts are discussing RXRX's recent performance and its outlook in the context of industry trends and global economic factors.
*   **2025-07-22:** RXRX's stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **2025-07-25:** Market experts highlight both risks and opportunities for RXRX, advising investors to monitor recent news and company announcements.

**Analysis:** Recent news suggests significant events and volatility surrounding RXRX, requiring careful monitoring of company announcements and market analysis.

### 5. Recent Earnings Analysis

| 날짜         | EPS   | 매출      |
| :----------- | :---- | :-------- |
| 2025-05-05 | -0.5  | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2024-08-08 | -0.4  | 0.01 B$  |
| 2024-05-09 | -0.39 | 0.01 B$  |
| 2025-05-05 | -0.39 | 0.01 B$  |

**Analysis:** RXRX has consistently reported negative Earnings Per Share (EPS) and relatively low revenue over the observed quarters. This indicates ongoing losses and a potential need for improved financial performance.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
| :----------- | :------ | :------------ |
| 2025-03-31 | \$0.01B | -47.31%       |
| 2024-12-31 | \$0.00B | -183.62%      |
| 2024-09-30 | \$0.03B | 53.69%        |
| 2024-06-30 | \$0.01B | 36.14%        |
| 2024-03-31 | \$0.01B | 17.23%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE       |
| :----------- | :------ | :-------- |
| 2025-03-31 | \$0.93B | -21.68%   |
| 2024-12-31 | \$1.03B | -17.29%   |
| 2024-09-30 | \$0.52B | -18.27%   |
| 2024-06-30 | \$0.58B | -16.69%   |
| 2024-03-31 | \$0.40B | -22.78%   |

**Analysis:**  Revenue has been inconsistent, ranging from \$0.00B to \$0.03B. Profit margins have been mostly negative, indicating poor cost management. While equity levels are relatively high, the Return on Equity (ROE) has been consistently negative, showing an inefficient use of equity to generate profits.

### 7. Overall Summary

Recursion Pharmaceuticals Inc. (RXRX) has significantly underperformed the S&P 500. Recent price action shows a short-term upward trend, but the RSI indicates the stock may be overbought. The MRI suggests low market risk, but the expected return is significantly negative. The company has consistently reported negative EPS and ROE, indicating ongoing losses. Recent news suggests significant events and volatility. The hybrid signal cautiously advises buying. Overall, RXRX presents a high-risk investment opportunity requiring careful monitoring and consideration of the company's financial performance and market developments.
